Cytokines in orthopaedic practice: A review

Current Orthopaedics

Volumn 17, Issue 5, 2003, Pages 378-385

  Raman, R ^a   Pape, H C ^b   Giannoudis, P V ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; COLONY STIMULATING FACTOR; CYTOKINE; CYTOKINE RECEPTOR; FAS LIGAND; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 18; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA;

ARTHROPLASTY; CYTOKINE RESPONSIVE ELEMENT; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; INFLAMMATION; INJURY; LYMPHOCYTE; LYMPHOCYTE FUNCTION; MEDICAL PRACTICE; OSTEOLYSIS; PRIORITY JOURNAL; REVIEW; SEPSIS; T LYMPHOCYTE;

EID: 0344873202     PISSN: 02680890     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-0890(03)00109-9     Document Type: Review

References (74)

1. Granger D N, Kubes P. The microcirculation and inflammation: modulation of leukocyte-endothelial cell adhesion. J Leukoc Biol 1994; 55:662-675.
2. Peduzzi P, Shatney C, Sheagren J, Sprung C. Predictors of bacteremia and gram-negative bacteremia in patients with sepsis. The Veterans Affairs Systemic Sepsis Cooperative Study Group. Arch Intern Med 1992; 152:529-535.
3. Hack C E, Hart M, van Schijndel R J et al. Interleukin-8 in sepsis: relation to shock and inflammatory mediators. Infect Immun 1992; 60:2835-2842.
4. Damas P, Ledoux D, Nys M et al. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 1992; 215:356-362.
5. Pinsky M R, Vincent J L, Deviere J, Alegre M, Kahn R J, Dupont E. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 1993; 103:565-575.
6. Cain B S, Meldrum D R, Harken A H, McIntyre Jr R C. The physiologic basis for anticytokine clinical trials in the treatment of sepsis. J Am Coll Surg 1998; 186:337-350.
7. Abraham E, Glauser M P, Butler T et al. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group. JAMA 1997; 277:1531-1538.
8. Abraham E, Wunderink R, Silverman H et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 1995; 273:934-941.
9. Cohen S, Hurd E, Cush J et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-I receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46:614-624.
10. Dumonde D C, Wolstencroft R A, Panayi G S, Matthew M, Morley J, Howson W T. 'Lymphokines': non-antibody mediators of cellular immunity generated by lymphocyte activation. Nature 1969; 224:38-42.
11. Gery I, Gershon R K, Waksman B H. Potentiation of cultured mouse thymocyte responses by factors released by peripheral leucocytes. J Immunol 1971; 107:1778-1780.
12. Diamantstein T, Handschumacher R E, Oppenheim J J et al. Nonspecific 'lymphocyte activating' factors produced by macrophages. J Immunol 1979; 122:2633-2635.
13. Hack C E, Aarden L A, Thijs L G. Role of cytokines in sepsis. Adv Immunol 1997; 66:101-195.
14. Smith R M, Giannoudis P V. Trauma and the immune response. J R Soc Med 1998; 91:417-420.
15. Moore F A, Moore E E. Evolving concepts in the pathogenesis of postinjury multiple organ failure. Surg Clin North Am 1995; 75:257-277.
16. Guirao X, Lowry S F. Biologic control of injury and inflammation: much more than too little or too late. World J Surg 1996; 20: 437-446.
17. Lin E, Lowry S F. The human response to endotoxin. Sepsis 1998; 2:255-262.
18. Lin E, Calvano S E, Lowry S F. Inflammatory cytokines and cell response in surgery. Surgery 2000; 127:117-126.
19. Pomerantz B J, Reznikov L L, Harken A H, Dinarello C A. Inhibition of caspase I reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta. Proc Natl Acad Sci USA 2001; 98:2871-2876.
20. Raeburn C D, Sheppard F, Barsness K A, Arya J, Harken A H. Cytokines for surgeons. Am J Surg 2002; 183:268-273.
21. Bresnihan B, Alvaro-Gracia J M, Cobby M et al. Treatment of rheumatoid arthritis with recombinant human interleukin-I receptor antagonist. Arthritis Rheum 1998; 41:2196-2204.
22. van Berge Henegouwen M I, van der Poll T, van Deventer S J, Gouma D J. Peritoneal cytokine release after elective gastro-intestinal surgery and postoperative complications. Am J Surg 1998; 175:311-316.
23. Cain B S, Meldrum D R, Dinarello C A et al. Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function. Crit Care Med 1999; 27:1309-1318.
24. Krown KA, Page M T, Nguyen C et al. Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest 1996; 98:2854-2865.
25. van der Poll T, Lowry S F. Tumor necrosis factor in sepsis: mediator of multiple organ failure or essential part of host defense? Shock 1995; 3:1-12.
26. Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson R C. Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature 1990; 348:550-552.
27. Xing Z, Gauldie J, Cox G et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest 1998; 101:311-320.
28. Biffl W L, Moore E E, Moore F A, Barnett Jr C C, Carl V S, Peterson V N. Interleukin-6 delays neutrophil apoptosis. Arch Surg 1996; 131:24-29; discussion 29-30.
29. Partrick D A, Moore F A, Moore E E, Biffl W L, Sauaia A, Barnett Jr C C, Jack A. Barney Resident Research Award winner. The inflammatory profile of interleukin-6, interleukin-8, and soluble intercellular adhesion molecule-I in postinjury multiple organ failure. Am J Surg 1996; 172:425-429; discussed 429-431.
30. Ward S G, Westwick J. Chemokines: understanding their role in T-lymphocyte biology. Biochem J 1998; 333 (Part 3):457-470.
31. DeForge L E, Preston A M, Takeuchi E, Kenney J, Boxer L A, Remick D G. Regulation of interleukin 8 gene expression by oxidant stress. J Biol Chem 1993; 268:25568-25576.
32. Carson W E, Yu H, Dierksheide J, Pfeffer K et al. A fatal cytokine-induced systemic inflammatory response reveals a critical role for NK cells. J Immunol 1999; 162:4943-4951.
33. Puren A J, Fantuzzi G, Dinarello C A. Gene expression, synthesis, and secretion of interleukin 18 and interleukin 1beta are differentially regulated in human blood mononuclear cells and mouse spleen cells. Proc Natl Acad Sci USA 1999; 96:2256-2261.
34. Bohn E, Sing A, Zumbihl R et al. IL-18 (IFN-gamma-inducing factor) regulates early cytokine production in, and promotes resolution of, bacterial infection in mice. J Immunol 1998; 160:299-307.
35. Tsutsui H, Matsui K, Kawada N et al. IL-18 accounts for both TNF-alpha- and Fas ligand-mediated hepatotoxic pathways in endotoxin-induced liver injury in mice. J Immunol 1997; 159:3961-3967.
36. Oberholzer A, Steckholzer U, Okamura H, Kurimoto M, Trentz O, Ertel W. Increased circulating levels of interleukin-18 during severe sepsis in humans. Surg Forum 1998; 49:88-90.
37. Dinarello C A. IL-18: a TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol 1999; 103:11-24.
38. Heinzel F P, Rerko R M, Ling P, Hakimi J, Schoenhaut D S. Interleukin 12 is produced in vivo during endotoxemia and stimulates synthesis of gamma interferon. Infect Immun 1994; 62:4244-4249.
39. Barbul A, Regan M C. The regulatory role of T lymphocytes in wound healing. J Trauma 1990; 30:S97-100.
40. Ertel W, Keel M, Infanger M, Ungethum U, Steckholzer U, Trentz O. Circulating mediators in serum of injured patients with septic complications inhibit neutrophil apoptosis through up-regulation of protein-tyrosine phosphorylation. J Trauma 1998; 44:767-775; discussion 775-776.
41. Fanning N F, Kell M R, Shorten G D et al. Circulating granulocyte macrophage colony-stimulating factor in plasma of patients with the systemic inflammatory response syndrome delays neutrophil apoptosis through inhibition of spontaneous reactive oxygen species generation. Shock 1999; 11:167-174.
42. Green D R, Ware C F. Fas-ligand: privilege and peril. Proc Natl Acad Sci USA 1997; 94:5986-5990.
43. Abraham E, Regan R F. The effects of hemorrhage and trauma on interleukin 2 production. Arch Surg 1985; 120:1341-1344.
44. Oka M, Hirazawa K, Yamamoto K et al. Induction of Fas-mediated apoptosis on circulating lymphocytes by surgical stress. Ann Surg 1996; 223:434-440.
45. Wang H Y, Paul W E, Keegan A D. IL-4 function can be transferred to the IL-2 receptor by tyrosine containing sequences found in the IL-4 receptor alpha chain. Immunity 1996; 4:113-121.
46. Mangan D F, Wahl S M. Differential regulation of human monocyte programmed cell death (apoptosis) by chemotactic factors and pro-inflammatory cytokines. J Immunol 1991; 147:3408-3412.
47. Marshall J D, Aste-Amezaga M, Chehimi S S, Murphy M, Olsen H, Trinchieri G. Regulation of human IL-18 mRNA expression. Clin Immunol 1999; 90:15-21.
48. Giannoudis P V, Smith R M, Perry S L, Windsor A J, Dickson R A, Bellamy M C. Immediate IL-10 expression following major orthopaedic trauma: relationship to anti-inflammatory response and subsequent development of sepsis. Intens Care Med 2000; 26:1076-1081.
49. Zlotnik A, Moore K W. Interleukin 10. Cytokine 1991; 3:366-371.
50. Minty A, Chalon P, Derocq J M et al. Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature 1993; 362:248-250.
51. Muchamuel T, Menon S, Pisacane P, Howard M C, Cockayne D A. IL-13 protects mice from lipopolysaccharide-induced lethal endotoxemia: correlation with down-modulation of TNF-alpha, IFN-gamma, and IL-12 production. J Immunol 1997; 158: 2898-2903.
52. Wong M L, Bongiorno P B, Rettori V, McCann S M, Licinio J. Interleukin (IL) 1beta, IL-1 receptor antagonist, IL-10, and IL-13 gene expression in the central nervous system and anterior pituitary during systemic inflammation: pathophysiological implications. Proc Natl Acad Sci USA 1997; 94:227-232.
53. Chomarat P, Banchereau J. Interleukin-4 and interleukin-13: their similarities and discrepancies. Int Rev Immunol 1998; 17:1-52.
54. Manna S K, Aggarwal B B. Interleukin-4 down-regulates both forms of tumor necrosis factor receptor and receptor-mediated apoptosis, NF-kappaB, AP-1, and c-Jun N-terminal kinase. Comparison with interleukin-13. J Biol Chem 1998; 273: 33333-33341.
55. Etter H, Althaus R, Eugster H P, Santamaria-Babi L F, Weber L, Moser R. IL-4 and IL-13 downregulate rolling adhesion of leukocytes to IL-1 or TNF-alpha-activated endothelial cells by limiting the interval of E-selectin expression. Cytokine 1998; 10:395-403.
56. Bone R C. Important new findings in sepsis. JAMA 1997; 278:249.
57. Rangel-Frausto M S, Pittet D, Costigan M, Hwang T, Davis C S, Wenzel R P. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995; 273:117-123.
58. Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987; 1:355-357.
59. Martin C, Saux P, Mege J L, Perrin G, Papazian L, Gouin F. Prognostic values of serum cytokines in septic shock. Intens Care Med 1994; 20:272-277.
60. Hershman M J, Cheadle W G, Wellhausen S R, Davidson P F, Polk Jr H C. Monocyte HLA-DR antigen expression characterizes clinical outcome in the trauma patient. Br J Surg 1990; 77:204-207.
61. Hershman M J, Appel S H, Wellhausen S R, Sonnenfeld G, Polk Jr H C. Interferon-gamma treatment increases HLA-DR expression on monocytes in severely injured patients. Clin Exp Immunol 1989; 77:67-70.
62. Oberhoffer M, Vogelsang H, Russwurm S, Hartung T, Reinhart K. Outcome prediction by traditional and new markers of inflammation in patients with sepsis. Clin Chem Lab Med 1999; 37:363-368.
63. Lisignoli G, Toneguzzi S, Pozzi C et al. Proinflammatory cytokines and chemokine production and expression by human osteoblasts isolated from patients with rheumatoid arthritis and osteoarthritis. J Rheumatol 1999; 26:791-799.
64. Bernard G R, Vincent J L, Laterre P F et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709.
65. DeLa Cadena R A, Majluf-Cruz A, Stadnicki A et al. Recombinant tumor necrosis factor receptor p75 fusion protein (TNFR:Fc) alters endotoxin-induced activation of the kinin, fibrinolytic, and coagulation systems in normal humans. Thromb Haemostasis 1998; 80:114-118.
66. Lassus J, Waris V, Xu J W et al. Increased interleukin-8 (IL-8) expression is related to aseptic loosening of total hip replacement. Arch Orthop Trauma Surg 2000; 120:328-332.
67. Gallo J, Kaminek P, Ticha V, Rihakova P, Ditmar R. Particle disease. A comprehensive theory of periprosthetic osteolysis: a review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2002; 146:21-28.
68. Xu J W, Li T F, Partsch G, Ceponis A, Santavirta S, Konttinen Y T. Interleukin-11 (IL-11) in aseptic loosening of total hip replacement (THR). Scand J Rheumatol 1998; 27:363-367.
69. Granchi D, Verri E, Ciapetti G et al. Bone-resorbing cytokines in serum of patients with aseptic loosening of hip prostheses. J Bone Joint Surg Br 1998; 80:912-917.
70. Konttinen Y T, Xu J W, Waris E et al. Interleukin-6 in aseptic loosening of total hip replacement prostheses. Clin Exp Rheumatol 2002; 20:485-490.
71. Moreschini O, Fiorito S, Magrini L, Margheritini F, Romanini L. Markers of connective tissue activation in aseptic hip prosthetic loosening. J Arthroplasty 1997; 12:695-703.
72. Campbell P A, Wang M, Amstutz H C, Goodman S B. Positive cytokine production in failed metal-on-metal total hip replacements. Acta Orthop Scand 2002; 73:506-512.
73. Suh K T, Chang J W, Jung J S. The role of inducible nitric oxide synthase in aseptic loosening after total hip arthroplasty. J Bone Joint Surg Br 2002; 84:753-775.
74. Lavigne P, Shi Q, Jolicoeur F C, Pelletier J P, Martel-Pelletier J, Fernandes J C. Modulation of IL-1beta, IL-6, TNF-alpha and PGE(2) by pharmacological agents in explants of membranes from failed total hip replacement. Osteoarthr Cartilage 2002; 10:898-904.